Christopher Ryan Sullivan Sells 8,458 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Ryan Sullivan sold 8,458 shares of the company’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $13.09, for a total transaction of $110,715.22. Following the completion of the sale, the chief financial officer directly owned 8,880 shares of the company’s stock, valued at $116,239.20. The trade was a 48.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Ryan Sullivan also recently made the following trade(s):

• On Thursday, April 30th, Christopher Ryan Sullivan sold 8,457 shares of Avalo Therapeutics stock. The stock was sold at an average price of $13.23, for a total transaction of $111,886.11.
• On Thursday, April 2nd, Christopher Ryan Sullivan sold 7,980 shares of Avalo Therapeutics stock. The stock was sold at an average price of $17.15, for a total transaction of $136,857.00.
• On Wednesday, April 1st, Christopher Ryan Sullivan sold 7,979 shares of Avalo Therapeutics stock. The stock was sold at an average price of $16.77, for a total transaction of $133,807.83.

Avalo Therapeutics Stock Up 2.3%

AVTX stock opened at $13.71 on Friday. The company has a market capitalization of $366.19 million, a P/E ratio of -2.39 and a beta of 0.78. The company has a 50-day simple moving average of $15.29 and a 200 day simple moving average of $16.21. Avalo Therapeutics, Inc. has a fifty-two week low of $3.39 and a fifty-two week high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($1.54) by $1.17. The company had revenue of $0.06 million during the quarter, compared to analyst estimates of ($0.21) million. Equities analysts anticipate that Avalo Therapeutics, Inc. will post -4.04 EPS for the current year.

Wall Street Analyst Weigh In

AVTX has been the subject of a number of research analyst reports. Guggenheim initiated coverage on shares of Avalo Therapeutics in a report on Monday, February 2nd. They issued a “buy” rating and a $50.00 price target for the company. Wall Street Zen raised shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, March 29th. Citizens Jmp initiated coverage on shares of Avalo Therapeutics in a report on Monday, April 6th. They issued an “outperform” rating and a $52.00 price target for the company. HC Wainwright upped their price target on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Wednesday, April 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Avalo Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $44.83.

Institutional Investors Weigh In On Avalo Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Orbimed Advisors LLC lifted its holdings in Avalo Therapeutics by 39.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock valued at $17,150,000 after acquiring an additional 382,300 shares during the last quarter. Nantahala Capital Management LLC raised its holdings in Avalo Therapeutics by 24.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock worth $15,697,000 after buying an additional 240,000 shares during the period. Affinity Asset Advisors LLC raised its holdings in Avalo Therapeutics by 4.5% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company’s stock worth $19,087,000 after buying an additional 44,837 shares during the period. Caligan Partners LP raised its holdings in Avalo Therapeutics by 5.8% during the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock worth $16,009,000 after buying an additional 48,200 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in Avalo Therapeutics during the 3rd quarter worth about $10,390,000. 87.06% of the stock is owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.